Uroplasty's Macroplastique® Implants: Received USFDA Pre-Market Approval
Filed in archive Diagnostics by Gloria Gamat on November 03, 2006

Uroplasty can now begin marketing Macroplastique® in the United States for the treatment of female stress urinary incontinence
primarily due to intrinsic sphincter deficiency.According to Uroplasty President and CEO, David B. Kaysen:
"We have been selling Macroplastique in Europe since 1991 and this approval allows us to commercialize the product in the United States. We expect to begin marketing this product in the United States in early 2007.
The addition of Macroplastique to the U.S. product line provides Uroplasty with the unique opportunity to treat multiple indications of voiding dysfunctions with a platform of safe and effective products."
Read the full press release (a pdf file).
Permalink: Uroplasty's Macroplastique® Implants: Received USFDA Pre-Market Approval
Tags:
urinary incontinence Macroplastique usfda uroplasty received+usfda usfda+market macroplastiqueÂ
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/41375








